Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 390

1.

Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone.

Raskin P, McGill J, Saad MF, Cappleman JM, Kaye W, Khutoryansky N, Hale PM; Repaglinide/Rosiglitazone Study Group.

Diabet Med. 2004 Apr;21(4):329-35.

PMID:
15049934
2.

Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone.

Jovanovic L, Hassman DR, Gooch B, Jain R, Greco S, Khutoryansky N, Hale PM.

Diabetes Res Clin Pract. 2004 Feb;63(2):127-34.

PMID:
14739053
3.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
4.

Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with Type 2 diabetes inadequately controlled on metformin alone.

Hamann A, Garcia-Puig J, Paul G, Donaldson J, Stewart M.

Exp Clin Endocrinol Diabetes. 2008 Jan;116(1):6-13. Epub 2007 Dec 20.

PMID:
18095238
5.

Repaglinide versus nateglinide monotherapy: a randomized, multicenter study.

Rosenstock J, Hassman DR, Madder RD, Brazinsky SA, Farrell J, Khutoryansky N, Hale PM; Repaglinide Versus Nateglinide Comparison Study Group.

Diabetes Care. 2004 Jun;27(6):1265-70.

PMID:
15161773
6.

Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin.

Raskin P, Klaff L, McGill J, South SA, Hollander P, Khutoryansky N, Hale PM; Repaglinide vs. Nateglinide Metformin Combination Study Group.

Diabetes Care. 2003 Jul;26(7):2063-8. Erratum in: Diabetes Care. 2003 Sep;26(9):2708.

PMID:
12832314
8.

Repaglinide/troglitazone combination therapy: improved glycemic control in type 2 diabetes.

Raskin P, Jovanovic L, Berger S, Schwartz S, Woo V, Ratner R.

Diabetes Care. 2000 Jul;23(7):979-83.

9.

Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.

Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G.

Diabetes Care. 2006 Mar;29(3):554-9.

PMID:
16505505
10.
11.

Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus.

Bosi E, Dotta F, Jia Y, Goodman M.

Diabetes Obes Metab. 2009 May;11(5):506-15. doi: 10.1111/j.1463-1326.2009.01040.x. Epub 2009 Mar 23.

PMID:
19320662
12.

Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy.

Garber A, Klein E, Bruce S, Sankoh S, Mohideen P.

Diabetes Obes Metab. 2006 Mar;8(2):156-63.

PMID:
16448519
13.

Randomized study of repaglinide alone and in combination with metformin in Chinese subjects with type 2 diabetes naive to oral antidiabetes therapy.

Wang W, Bu R, Su Q, Liu J, Ning G.

Expert Opin Pharmacother. 2011 Dec;12(18):2791-9. doi: 10.1517/14656566.2011.602341. Epub 2011 Jul 22.

PMID:
21780853
14.

Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.

Ushakova O, Sokolovskaya V, Morozova A, Valeeva F, Zanozina O, Sazonova O, Zhadanova E, Starceva M, Kazakova E, Saifullina M, Shapiro I, Tarasov A, Al-Tayar B, Starkova N.

Clin Ther. 2007 Nov;29(11):2374-84.

PMID:
18158078
15.

Initial treatment with fixed-dose combination rosiglitazone/glimepiride in patients with previously untreated type 2 diabetes.

Chou HS, Palmer JP, Jones AR, Waterhouse B, Ferreira-Cornwell C, Krebs J, Goldstein BJ.

Diabetes Obes Metab. 2008 Aug;10(8):626-37. Epub 2007 Jul 21.

PMID:
17645558
18.

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.

Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG.

Clin Ther. 2008 Aug;30(8):1448-60. doi: 10.1016/j.clinthera.2008.08.006. Erratum in: Clin Ther. 2008 Oct;30(10):1937.

PMID:
18803987
20.

Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes.

Moses R, Slobodniuk R, Boyages S, Colagiuri S, Kidson W, Carter J, Donnelly T, Moffitt P, Hopkins H.

Diabetes Care. 1999 Jan;22(1):119-24.

Items per page

Supplemental Content

Write to the Help Desk